Stay up to date with our newsletter

Get in touch!

What can we do to help?

I would like to:

Lets start the conversation!

Sign up to our newsletter

View open positions on our Careers page,
or connect with us on Linkedin Twitter Facebook Youtube

Thank you!
We will be in touch shortly.

2020.01.10

Dr. Mark Bittinger joins Sai Life Sciences as Global Head of Biology

Dr. Mark Bittinger

Sai Life Sciences, one of India’s fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced the appointment of Dr. Mark Bittinger as Vice President and Global Head of Biology. Mark will be based out of the company’s new Discovery Biology facility in Cambridge, Massachusetts, USA, which provides exploratory biology capabilities to the expanding array of start-up and biotech companies in the region.

Mark Bittinger is an acknowledged leader in the area of oncology drug discovery / translational science and has over 25 years of experience across immune-oncology, epigenetics, and tumor cell metabolism. With over 20 research publications to his credit, Mark has had a stellar track record in research, innovation & cross-functional leadership in organizations such as Merck Research Labs, Dana-Farber Cancer Institute, Agios Pharmaceuticals, and Novartis Institute of BioMedical Research. Mark received his B.A. from The Johns Hopkins University and followed with a Ph.D. in Cellular & Molecular Biology from the University of Wisconsin, Madison.

Located in the heart of the Cambridge/Boston biotech ecosystem, Sai’s new 8,500 square feet lab in Kendall Square creates opportunities for biotechs to have face-to-face collaboration with Sai scientists, and to accelerate the pace of their externalized research by reducing cycle-times. The lab provides exploratory biology capabilities using state-of-the-art platforms and technologies such as high-content microscopy, CRISPR-mediated genome editing, flow cytometry/sorting, and high-throughput patch-clamp platforms to address unique client needs. These activities include new target and biomarker identification and/or validation and establishing in vitro and cell-based assays for established targets.

The Cambridge lab serves as a vital bridge, enabling seamless integration with rest of the company’s service offerings across UK and India, spanning the drug discovery and development continuum including medicinal chemistry, DMPK and toxicology, process chemistry and analytical development, and commercial scale manufacturing.

Sai Life Sciences is currently in the midst of an organization-wide initiative, Sai Nxt that is aimed at transforming the company into a new generation CDMO. With investments of over US$150 million between 2019 and 2023, the focus is on three key areas – people & culture, processes & automation, infrastructure & scientific capabilities.

Commenting on his appointment, Mark Bittinger said, " I am incredibly excited to join Sai Life Sciences as we open the doors at our new Cambridge site. Here we will deliver exploratory biology capabilities to accelerate our clients’ ability to build value and deliver tomorrow's medicines."

News

2020.09.10

Discovery Biology Laboratory in Cambridge, MA, USA

Sai Life Sciences expands suite of cellular analysis platforms in Cambridge, MA

Sai Life Sciences today announced the addition of state-of-the-art cellular analysis platforms at its Discovery Biology facility in Cambridge, Massachusetts, USA. Coinciding with its first anniversary in Cambridge, the expanded suite of capabilities include the Opera Phenix high content screening platform, FACSCelesta flow cytometer and FACSMelody flow sorter, enabling it to better serve start-up and […]
Read more

2020.09.04

21st National Award for Excellence in Energy Management 2020

Sai Life Sciences receives the 21st National Award for Excellence in Energy Management 2020

Sai Life Sciences won the prestigious 21st National Award for Excellence in Energy Management 2020 hosted by CII – Sohrabji Godrej Green Business Centre, for its Manufacturing facility in Bidar, Karnataka. It was recognized as an “Energy Efficient Unit” under the ‘General Sector’ category for driving energy-efficient and sustainable practices to reduce CO2 gas emissions […]
Read more

2020.08.26

ACS Green Chemistry Institute Pharmaceutical Roundtable

Sai Life Sciences joins the ACS Green Chemistry Institute Pharmaceutical Roundtable

Sai Life Sciences today announced its induction to the ACS Green Chemistry Institute Pharmaceutical Roundtable (ACS-GCIPR) as an ‘Associate Member’. The company has been committed to increasing the adoption of Green Chemistry principles in its process development and instituted its inaugural ‘Green Chemistry Awards’ last year, to recognize and celebrate teams that make notable contributions […]
Read more

2020.08.15

Sai Life Sciences opens new, state-of-the-art Research & Technology Centre in Hyderabad

• Completes first phase in committed investment of US$ 150M (> INR 1000 Cr) • Sri KT Rama Rao, Hon’ble Minister for Industry & Commerce and IT, Government of Telangana inaugurates the facility Sai Life Sciences, one of India’s fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced the inauguration of its new Research […]
Read more

2020.06.01

Ensuring manufacturing continuity during the pandemic

Ensuring manufacturing continuity during the pandemic. Together.

‘Make it better together’ is a guiding tenet for how we operate each day. Yet, as it often does during a crisis, a truly collaborative effort during the present pandemic involving all our supply partners, airline & shipping companies, freight forwarders, transporters and our own cross-functional teams, has emphatically reinforced this belief. It has allowed […]
Read more